Jessica Jensen

Direttore Tecnico/Scientifico/R&S presso POINT Biopharma, Inc. (United States)

44 anni

Health Technology

Consumer Services

Commercial Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Joe McCann	M	47	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 anni
Neil Fleshner	M	60	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 anni
Allan Silber	M	75	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 anni
Ari Shomair	M	-	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
William Demers	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 anni
Gerald Hogue	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 anni
Justyna Kelly	F	39	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	3 anni
David Mims	M	60	PROGENICS PHARMACEUTICALS, INC.	5 anni
Jonathan Goodman	M	56	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 anni
Margaret Gilmour	F	64	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 anni
Philip Johnson	M	59	POIT BIOP	1 anni
Michael Gottlieb	M	45	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 anni
Michael Thompson	M	-	POIT BIOP	1 anni
Gerry Hogue	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Peggy Gilmour	F	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Howard M. Glase	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Gordon Brooks	M	-	POIT BIOP	1 anni
Chris Anderson	M	-	POIT BIOP	1 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Mark Robert Baker	M	69	PROGENICS PHARMACEUTICALS, INC.	14 anni
Peter J. Crowley	M	65	PROGENICS PHARMACEUTICALS, INC.	10 anni
Angelo William Lovallo	M	59	PROGENICS PHARMACEUTICALS, INC.	7 anni
Nicole S. Williams	F	79	PROGENICS PHARMACEUTICALS, INC.	12 anni
Patrick Fabbio	M	56	PROGENICS PHARMACEUTICALS, INC.	5 anni
Rajesh K. Malik	M	65	POIT BIOP	2 anni
Bridget Martell	M	58	POIT BIOP	-
Karen Ferrante	M	66	PROGENICS PHARMACEUTICALS, INC.	6 anni
Bradley Campbell	M	48	PROGENICS PHARMACEUTICALS, INC.	4 anni
Mary Heino	F	64	PROGENICS PHARMACEUTICALS, INC.	-
Yael Margolin	M	70	POIT BIOP	2 anni
David Lubner	M	60	POIT BIOP	2 anni
Ann MacDougall	F	70	PROGENICS PHARMACEUTICALS, INC.	1 anni
Michael Kishbauch	M	75	PROGENICS PHARMACEUTICALS, INC.	6 anni
Robert J. Israel	M	67	PROGENICS PHARMACEUTICALS, INC.	21 anni
David Scheinberg	M	68	PROGENICS PHARMACEUTICALS, INC.	25 anni
Jeffrey D. Summer	M	64	PROGENICS PHARMACEUTICALS, INC.	3 anni
Robin Hallett	M	-	POIT BIOP	-
Thomas Strack	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Sherin Al-Safadi	M	-	POIT BIOP	-
Myra Rosario Herrle	M	-	POIT BIOP	2 anni
Syed Mahmood	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Daniel Pearlstein	M	-	POIT BIOP	2 anni
Aseem Anand	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Chris Horvath	M	-	POIT BIOP	1 anni
Donna Husack	F	-	POIT BIOP	3 anni
Hagop Youssoufian	M	67	PROGENICS PHARMACEUTICALS, INC.	1 anni
Bryce V. Tenbarge	M	51	PROGENICS PHARMACEUTICALS, INC.	-
Asha Das	M	59	PROGENICS PHARMACEUTICALS, INC.	-
Robert Marshall	M	57	PROGENICS PHARMACEUTICALS, INC.	-
Matthew Vincent	M	-	POIT BIOP	1 anni
Heinz Christoph Mäusli	M	61	PROGENICS PHARMACEUTICALS, INC.	1 anni
Gérard Ber	M	66	PROGENICS PHARMACEUTICALS, INC.	1 anni
Nitya G. Ray	M	71	PROGENICS PHARMACEUTICALS, INC.	17 anni
Sheldon Hirt	M	60	PROGENICS PHARMACEUTICALS, INC.	1 anni
Eric Ende	M	55	PROGENICS PHARMACEUTICALS, INC.	1 anni
Melita Sequeira	F	-	POIT BIOP	-

Statistiche

Paese	Relazioni	% del totale
Stati Uniti	55	100.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni